Cryoport, Inc. (CYRX) - 10-K Summary
Business Context and Reporting Period
Company: Cryoport, Inc.
Filing Type: Annual Report on Form 10-K
Fiscal Year Ended: March 31, 2008
Reporting Date: June 30, 2008
Cryoport is a cryogenic transport container company focused on the safe transport of biological specimens at temperatures below zero centigrade. The company is currently in a strategic transition, shifting focus from its existing line of reusable cryogenic dry shippers to the development and launch of the "CryoPort Express" One-Way Shipper System. This new product line utilizes lower-cost materials and automated manufacturing to create disposable, single-use shipping containers for the pharmaceutical and biotechnology industries.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Net Sales | $83,564 | $67,103 |
| Cost of Sales | $386,371 | $176,939 |
| Gross Loss | ($302,807) | ($109,836) |
| Operating Expenses (SG&A + R&D) | $2,717,005 | $1,987,085 |
| Interest Expense | $1,592,712 | $227,738 |
| Net Loss | ($4,564,054) | ($2,326,259) |
| Net Loss Per Share | ($0.12) | ($0.08) |
| Cash Used in Operating Activities | ($1,820,250) | Not explicitly stated |
| Total Assets (March 31, 2008) | $3,460,889 | $483,687 |
| Total Liabilities (March 31, 2008) | $3,461,070 | $2,771,519 |
| Cash & Cash Equivalents (June 26, 2008) | $2,483,127 | N/A |
Note: The company reported a significant increase in interest expense due to the amortization of discounts on convertible debentures ($1.21 million) and non-cash stock-based compensation charges.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 24.5% to $83,564, though absolute revenue remains minimal due to the strategic shift away from reusable shippers.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses increased by 34.3% to $2.55 million, driven primarily by $1.28 million in non-cash option and warrant charges. Research and Development (R&D) expenses increased by 89.2% to $166,227.
- Debt Financing: In October 2007, the company issued $4.7 million in convertible debentures (net proceeds $3.4 million). In May 2008, an additional $870,625 was raised via convertible debentures. Total indebtedness increased significantly to $3.46 million.
- Stock Issuances: The company issued 3.65 million shares of common stock in private placements during fiscal 2008, raising approximately $790,000 net of costs.
Outlook, Risks, and Management Commentary
Going Concern: The company's auditors have raised substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. Management states that recent financing provides sufficient capital to launch the CryoPort Express One-Way Shipper and sustain operations in the near term.
Strategic Focus: Management is phasing out the reusable shipper line (AR1000, DS650, DG1000) over the next 6 to 12 months to concentrate resources on the one-way system. The goal is to offer a cost-effective alternative to dry ice and expensive reusable containers for pharmaceutical clinical trials and vaccine distribution.
Risks and Contingencies:
- Liquidity: Continued reliance on debt and equity financing to fund operations and product development.
- Customer Concentration: In fiscal 2008, one distributor (Tegrant) accounted for 62% of sales volumes.
- Product Launch: No assurance that the CryoPort Express One-Way Shipper will achieve market acceptance or generate significant revenue.
- Related Party Debt: The company owes $1.25 million to five related parties (including former directors) and had missed payments on these notes as of March 31, 2008, though payments were subsequently made within the grace period.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the burn rate to confirm the timeline for the next financing round.
- Convertible Debt Terms: Review the conversion rates ($0.84 standard, with some adjustments to $0.70) and the potential for significant dilution upon conversion of the $4.4 million principal balance.
- Product Traction: Confirm if any firm purchase orders or revenue have been generated from the new CryoPort Express One-Way Shipper System since the filing date.
- Related Party Payments: Monitor the status of payments on the $1.25 million in related-party notes to ensure no default occurs.
- Stock Dilution: Assess the impact of the 29.6 million outstanding options and warrants (weighted average exercise price $0.51) on future share count.